Achi news desk-
Mavacamten, sold under the brand name Camzyos, is approved for the treatment of adults with the heart condition hypertrophic obstructive cardiomyopathy.
In the condition the muscle in the main chamber of the heart thickens or swells which can block the flow of blood to the rest of the body.
Joel Rose, chief executive of the charity Cardiomyopathy UK, said: “For people experiencing symptoms of obstructive hypertrophic cardiomyopathy, everyday life can be affected, and daily activities that we take for granted can sometimes become a challenge.
READ MORE: Charity provides over £7m to fund cancer research in Scotland
“Today’s news provides reassurance that the latest developments are now available to those who need them.
“We believe that everyone affected by obstructive hypertrophic cardiomyopathy deserves to live well, and we hope that this treatment option supports eligible patients.”
Dostarlimab, sold under the brand name Jemperli, is approved for the treatment of advanced endometrial cancer with a specific genetic mutation and is used in combination with chemotherapy.
Meanwhile, the Sleep Charity UK has welcomed the SMC’s decision to accept daridorexant, also known as Quviviq, for the treatment of adults with insomnia that has lasted more than three months.
The charity’s deputy chief executive, Lisa Artis, said: “For people living with chronic insomnia, the impact of their condition goes beyond trouble sleeping at night and can have far-reaching consequences for everyday life – affecting their their health and well-being and limit their ability. to work and do the things they enjoy.
“We want more people living with sleep conditions to get the support and treatment they need, so we welcome today’s decision to enable NHS patients in Scotland to access a new treatment option on for chronic insomnia.”
The other decisions announced on Monday were the acceptance of ritlecitinib, provided under the brand name Litfulo, for the treatment of severe alopecia areata in people aged 12 and over.
It is the first medicine that the SMC has approved for regular use for the treatment of alopecia areata, a condition that causes hair loss on the scalp and other parts of the body.
Tirzepatide, sold under the brand name Mounjaro, has been approved for the treatment of type 2 diabetes, alongside diet and exercise, while mirikizumab, also known as Omvoh, has been approved for the treatment of ulcerative colitis in adults.
And Glycopyrronium bromide/formoterol fumarate dihydrate, also known as Bevespi Aerosphere, is approved for the treatment of adults with chronic obstructive pulmonary disease (COPD).
SMC chairman Dr Scott Muir said: “We are delighted to be able to receive these seven new medicines for use by NHS Scotland.
“There are limited treatment options available for treating advanced endometrial cancer and we know that our decision on dostarlimab, which offers better outcomes compared to chemotherapy alone, will be welcomed by patients and clinicians.
“Alopecia can have a big impact on people’s quality of life. Ritlecitinib is the first medicine that SMC has accepted for this condition for routine use in the Scottish NHS.
“Our decision on mavacamten will be welcomed by patients with obstructive hypertrophic cardiomyopathy and their families, as it is the first licensed treatment to specifically target the underlying cause of the affected heart condition.
“Tirzepatide will provide a useful treatment option for people with type 2 diabetes.”
